Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 16/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | WNT1 | P04628 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834330 | 1.00 | CD38 (0.61) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL29182272 | 1.00 | CD38 (0.61) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL29182195 | 0.89 | CD38 (0.48) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL25136035 | 0.89 | CD38 (0.48) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL29182248 | 0.88 | CD38 (0.59) | CD38CYP2D6CYP2B6CYP2C19TNKS | |
| SCHEMBL25136240 | 0.88 | CD38 (0.59) | CD38CYP2D6CYP2B6CYP2C19TNKS | |
| SCHEMBL30363874 | 0.88 | CD38 (0.59) | CD38CYP2D6CYP2B6CYP2C19TNKS | |
| SCHEMBL25136495 | 0.85 | CD38 (0.49) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL30363822 | 0.85 | CD38 (0.49) | CD38CYP2D6CYP2B6CYP2C19WNT1 | |
| SCHEMBL29182179 | 0.85 | CD38 (0.49) | CD38CYP2D6CYP2B6CYP2C19WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885CYP2D6 1605/4885CYP2B6 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.